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ABSTRACT 
 
 
 
 
 
 
Herein is reported the first total synthesis of Aeruginazole A, prepared via a convergent strategy that involved both 
solid-phase peptide synthesis and solution phase chemistry and that enabled conservation of the stereochemistry of 
the intermediates. 
 
Aeruginazole A is a macrocyclic dodecapeptide that 
was recently isolated from the cyanobacterium 
Microcystis sp. strain (IL-323) and that exhibits inhibitory 
activity towards Bacillus subtilis.1 It is an interesting 
example of the numerous macrocyclic thiazole-containing 
compounds that have been isolated from natural sources 
over the past few decades and subsequently tested for 
biological activity, and whose extremely varied structures 
have been the targets of total syntheses.2 
The diverse combination of structural motifs in 
Aeruginazole A is interesting: its macrocycle comprises a 
pentapeptide of L-amino acids (known as the northern 
region), and a group of three thiazole moieties combined 
with a D-Tyr residue (the southern region). 
The presence of L- and D-amino acids, and of amino 
acid-derived moieties, in the compound is interesting, as 
is their location: the L-amino acids are located in the 
western and eastern regions only, whereas there are two 
consecutive D-amino acids in the southern region. The 
stereochemistry of the target molecule is therefore an 
important feature and a critical synthetic challenge. 
Intrigued by its peculiar structure and seeking to further 
explore its biological activity, we decided to undertake 
the total synthesis of Aeruginazole A. 
Work began with the retrosynthetic analysis 
represented in Figure 1: in addition to the northern 
pentapeptide 1, tyrosine3 5 and the optically active 
thiazole-building blocks 2-4 were identified through 
disconnections of the southern region of Aeruginazole A 
(Figure 1). 
The planned route to the stereodefined thiazole 
building blocks 2-4 was to subject precursor thioamides to 
Hantzsch thiazole synthesis. These precursors were 
readily accessed from Boc-L-Asp(OBzl)-OH, Boc-L-Val-
OH and Boc-D-Leu-OH. Commercially available N-
protected amino acids were converted into the 
corresponding primary amides 6a-8a (Scheme 1) through 
activation and subsequent treatment with concentrated 
aqueous ammonia. 
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Figure 1. Structure of Aeruginazole A and retrosynthetic analysis 
 
The Leu was activated for nucleophilic substitution 
through transformation into the corresponding methyl 
ester.4 Unfortunately, this easy protocol gave poor yields 
with Val and was incompatible with the benzyl ester 
group of protected Asp. Alternatively, these residues were 
activated by treatment with 2,2,2-trichloroethyl 
chloroformate. Each of the amides 6a-8a was then 
converted into its corresponding thioamide 6b-8b, 
respectively, using Lawesson’s reagent (LR).5 
The three thioamides were then subjected to Hantzsch 
thiazole syntheses, a critical point in the total synthesis, 
given the need to preserve the stereochemical information 
present in the thioamides themselves. First, classical 
conditions for this reaction were tested: the thioamides 
were treated with ethyl bromopyruvate and pyridine in 
refluxing ethanol.6 Optical purity was checked in the case 
of the known compound Val-thiazole 9 (Scheme 1) by 
comparison of its rotatory power with published data.7  
 
However, racemization of Leu-thiazole 10 and Asp-
thiazole 11 was detected further in the synthetic sequence: 
NMR spectra revealed formation of diastereomeric 
mixtures of products when 10 and 11 were converted into 
the more advanced synthetic intermediates 13 and 14, 
respectively (Scheme 3), each of which bears two 
stereocenters.8 Once a chiral HPLC analysis method for 
all three Hantzsch synthesis products had been 
established, racemization was definitively confirmed (see 
Experimental Procedures for details). Switching to Merritt 
and Bagley’s protocol9 (Scheme 1) for Hantzsch synthesis 
of stereodefined thiazoles provided the building blocks 9-
11 in 75-98% yields with conservation of optical purity 
(ee ranging from 91 to 94%). It should be noted that 
special care had to be paid to the dehydration step 
(Scheme 1, step ii). Lower-than-expected ee’s were 
observed when the reaction temperature was increased 
before the dehydration was complete. 
 
Scheme 1. Synthesis of thiazole moietiesa 
 
 
aReagents and conditions: (i) ethyl bromopyruvate, KHCO3, 
DME, -25 °C to rt, 24 h; (ii) TFAA, 2,6-lutidine, DME, -25 °C, 
3 to 4 h 
 
Therefore, termination of the step at -25 °C had to be 
carefully confirmed before the work up. Furthermore, the 
previously published work-up procedures had to be 
slightly modified to enable direct access to the desired 
compounds.10 
Once the Hantzsch products 9-11 were obtained in 
suitable optical purity, Asp-thiazole 11 was converted into 
the desired building block 12 (Scheme 2).  
 
 
Scheme 2. Synthesis of Asn-thiazole 12a 
 
 
aReagents and conditions: (a) H2, Pd/C, iPrOH, rt, 24 h, 93%; 
(b) PyBOP, N,N-diisopropylethylamine (DIEA), NH4HCO3, 
THF, DMF, 0 °C, 3 h, 68% 
 
The benzyl ester protecting group was cleanly removed 
by hydrogenolysis; the reaction was first attempted in 
MeOH but, unexpectedly, partial conversion of the acid to 
the corresponding methyl ester was observed (from trace 
amounts up to 53%). This problem was solved by running 
the reaction in iPrOH, which is more sterically hindered. 
Acid 11a was then converted into the corresponding 
amide 12. The conditions for this transformation had to be 
extensively investigated, since the initially tested 
activation strategies and NH3 sources gave low yields. 
Actually, activation as mixed anhydrides using either 
Boc2O11 or 2,2,2-trichloroethyl chloroformate, and use of 
alternative NH3 sources (conc. aq. NH3 or NH4Cl) never 
gave yields superior to 55%. However, better yields 
(68%) were obtained when benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate 
(PyBOP)12 was used as activating agent and ammonium 
bicarbonate was used as NH3 source. 
The building blocks 9, 10 and 12 were then 
deprotected. The ethyl ester of 9 was hydrolyzed with 2N 
LiOH to give compound 3; the Boc-protecting groups 
from 12 and 10 were removed with 4M HCl to afford 
their corresponding hydrochloride salts 2.HCl and 4.HCl, 
respectively (Scheme 3). At this stage, all the building 
blocks required for the southern peptide had been 
synthesized; the preparation of northern peptide was 
therefore addressed. 
Fmoc-protected pentapeptide 1 was smoothly 
synthesized by solid-phase peptide synthesis (SPPS) on 2-
chlorotritylchloride resin, first manually, through 
activation with diisopropyl carbodiimide and 1-
hydroxybenzotriazole (HOBt), then by adapting the 
procedure to automated microwave-assisted synthesis 
using O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HBTU) as coupling agent. 
Since the building blocks 1-4 (Figure 1) had been 
prepared, condensation of the individual synthetic 
intermediates was then undertaken. The coupling pattern 
(Scheme 3) was chosen according to the highest possible 
degree of convergence: Asn-thiazole 2.HCl was coupled 
to Boc-D-Tyr-OH, giving rise to building block 13 (91% 
yield), whereas D-Leu-thiazole 4.HCl was condensed with 
Val-thiazole 3 to form building block 14 (79% yield). 
Both couplings proceeded uneventfully (3 h at 0 °C) 
through activation by PyBOP. 
The amine 15 was then coupled to the acid 16 to form 
the tris-thiazole peptide 17. Interestingly, the yield of this 
reaction was strongly dictated by the ratio of amine to 
acid: whereas an excess (1.2 equiv) of acid 16 gave a 
disappointingly low yield (58%), an excess (1.6 equiv) of 
amine hydrochloride 15 allowed to increase the yield to 
92%. The Boc-protecting group was then removed from 
compound 17 (Scheme 3) to afford the southern peptide 
18, which was directly coupled to northern peptide 1. The 
protocol (PyBOP in THF) used in all previous couplings 
was again tested, but proved unsatisfactory in this case 
(yields of roughly 10%). Observed solubility issues, as 
well as a desire to minimize the amount of DIEA used, in 
consideration of the presence of the Fmoc group, were 
therefore addressed by switching to a different system, 
EDCI/HOBt in CH2Cl2/DMF, which gave a gratifying 
yield of 79%. At this stage, the entire linear skeleton of 
Aeruginazole A had been prepared and thiazole 
dodecapeptide 19 (Scheme 3) was ready for final 
hydrolysis of its ethyl ester group, cleavage of its Fmoc 
group and subsequent macrocyclization. Thus, compound 
19 was treated with LiOH in THF/H2O in a one-pot 
removal of the protecting groups on both ends of the 
peptide to give the acid 20. Macrocyclization of crude 20 
was then performed in high dilution conditions (2.5 mM 
in DMF) by activation with PyBOP and HOAt, affording 
the desired product in a 24% yield over the two steps of 
deprotection and cyclization . 
The spectroscopic data for this product fully agreed 
with those for a sample of natural product, thereby 
enabling confirmation of the structure proposed for 
Aeruginazole A by Raveh and Carmeli.1 In summary, 
Aeruginazole A was obtained in an overall yield of 4.3% 
through a convergent synthesis combining solution- and 
solid-phase procedures. Special care was paid to conserve 
the integrity of the stereocenters in the intermediates, via 
strict control of Hantzsch thiazole syntheses and through 
use of various peptide-coupling reagents. 
 
 
 
 
 
 Scheme 3. Total synthesis of Aeruginazole Aa 
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aReagents and conditions: (a) 5, PyBOP, DIEA, THF, 0 °C, 3 h, 91%; (b) 2M HCl, 1,4-dioxane, rt, 2 h, 95%; (c) 3, PyBOP, DIEA, THF, 0 
°C, 3h, 79%; (d) 2N LiOH, THF, rt, 48 h, 97%; (e) PyBOP, DIEA, THF, 0 °C, 3 h, 92%; (f) 2M HCl, 1,4-dioxane, MeOH, rt, 3 h, quant.; 
(g) 1, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI), HOBt, DIEA, CH2Cl2, DMF, rt, 5 h, 79%; (h) 2N LiOH, 
THF, H2O, rt, 4 h; (i) PyBOP, 1-hydroxy-7-azabenzotriazole (HOAt), DIEA, DMF, 0 °C to rt, 60 h, 24% from 19 
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